RO LAUNCHES ELI LILLY'S KWIKPEN®, OFFERING PATIENTS A MORE CONVENIENT WAY TO TAKE ZEPBOUND®

The most effective GLP-1 medication is now available in a multi-dose pen NEW YORK, April 2, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced that it is working with Eli Lilly to launch the recently FDA-approved Zepbound® (tirzepatide) KwikPen®...